(S002) A 15-Year Review of Radiation Therapy for Keloids at Two Institutions

Publication
Article
OncologyOncology Vol 30 No 4_Suppl_1
Volume 30
Issue 4_Suppl_1

For many individuals, keloids present a symptomatic and cosmetic issue after tissue injury. Surgical excision followed by immediate adjuvant RT provides excellent local control and cosmesis with minimal toxicity. Treatment with both prescribed regimens yielded equal results.

Paul B. Renz, DO, Mark Trombetta, MD, James Fontanesi, MD; Allegheny General Hospital; Botsford Cancer Center

INTRODUCTION: Keloids are a process of overactive wound repair after a resultant injury and affect people of all ancestries-in particular, African, Asian, and Hispanic populations. Pathologically, the keloids progress from a robust inflammatory reaction and tissue remodeling, with disordered fibroblast proliferation, cytokine production, and collagen deposition. Patients can experience symptoms of pain, pruritus, and physical deficit due to contracture. Keloids also cause significant cosmetic and psychosocial issues. Accordingly, most patients seek treatment for symptomatic keloids. Intralesional injection, silicone gel sheets, and pressure therapy are conservative treatment options; yet, often, patients need excision for symptomatic relief and cosmesis. However, surgical excision alone can result in an insidious cycle of tissue injury and repeat keloid formation unless combined with adjuvant therapy to halt this cycle. Postsurgical radiation therapy (RT) is effective in preventing redevelopment of keloid. We present our results on postoperative RT for keloids at two institutions.

METHODS: A retrospective review of the records at two academic institutions from 2000–present was conducted. A total of 107 patients were treated to 201 total sites. Patients had surgical resection followed by adjuvant RT initiated within 24 hours of surgery. Two dosage schemes were utilized: (1) 1,200 cGy in three fractions of 400 cGy and (2) 2,000 cGy in five fractions of 400 cGy. Patients were analyzed for local failure, defined as redevelopment of keloid necessitating retreatment.

RESULTS: Overall, there were eight (4%) local failures, with three in the 1,200-cGy arm and five in the 2,000-cGy arm (chi-square test, P =.94). Treatment failures were associated with overall size of keloid and location (pinna or areas of increased skin tension). There were no treatment-related toxicities or secondary malignancies.

CONCLUSIONS: For many individuals, keloids present a symptomatic and cosmetic issue after tissue injury. Surgical excision followed by immediate adjuvant RT provides excellent local control and cosmesis with minimal toxicity. Treatment with both prescribed regimens yielded equal results.

Proceedings of the 98th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(S002) A 15-Year Review of Radiation Therapy for Keloids at Two Institutions
(S003) Single-Fraction Radiation Therapy for the Treatment of Multiple Myeloma Bony Metastases Provides Pain Control and Decreases Time to Chemotherapy
(S001) Prognostic Value of Pretreatment Serum Inflammatory Markers in Patients Receiving Radiation Therapy for Oropharyngeal Cancer
(S004) Trend in Second Malignancy Risk for Head and Neck Cancer With Increased Utilization of IMRT: Analysis of SEER Database
(S005) Comparison of Legal Needs of a Group of Patients With Cancer: Economic and Geographic Factors
(S006) Mission Improvement: Lessons From Initiating a Resident-Led Quality Improvement Project on Smoking Cessation at a County Hospital
(S007) Results of a Phase II Trial Using Cetuximab Plus Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma
(S008) The Effect of Simulation and Treatment Delays for Patients With Oropharyngeal Cancer Receiving Definitive Radiation Therapy in the Era of Risk Stratification Using Smoking and Human Papilloma Virus Status
(S009) Intensity-Modulated Radiation Therapy With Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on Three-Year Toxicity
(S011) Comparative Study Between Ileal Conduit and Indiana Pouch After Cystectomy for Patients With Carcinoma of Urinary Bladder
(S010) Computed Tomography–Assessed Measures of Bone Mineral Density and Muscle Mass as Predictors of Survival in Men With Prostate Cancer
(S012) Quantitative Imaging to Evaluate the Malignant Potential of Pancreatic Cysts
(S013) Spine Stereotactic Radiosurgery With Concurrent Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
(S014) The Impact of Radiation Therapy on Survival in Surgically Resected, High-Risk Patients With Ampullary Adenocarcinoma: A Population-Based Analysis
(S016) The Impact of Stereotactic Body Radiation Therapy on Overall Survival in Patients With Locally Advanced Pancreatic Cancer
Related Videos
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Whether CAR T-cell therapy or T-cell engagers should dominate the multiple myeloma landscape may be hard to determine, says David S. Siegel, MD.
Next steps for research in the multiple myeloma space may include the development of novel CAR T-cell strategies and bispecific antibodies.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Adverse effects associated with oral azacitidine in low- or intermediate-risk MDS are typically transient, according to Mikkael A. Sekeres, MD, MS.
Related Content